Safety and biodistribution of 99mtechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3046-3055

  Stroomer, Joep W G ^a   Roos, Jan C ^a   Sproll, Marlies ^b   Quak, Jasper J ^a   Heider, Karl Heinz ^b   Wilhelm, Bram J ^a   Castelijns, Jonas A ^a   Meyer, Reiner ^b   Kwakkelstein, Marthin O ^c   Snow, Gordon B ^a   Adolf, Günther R ^b   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BIWA 1; TECHNETIUM 99M; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; CANCER ANTIBODY; CD44V6 ANTIGEN; DIAGNOSTIC AGENT; GLYCOPROTEIN; HERMES ANTIGEN; RADIOPHARMACEUTICAL AGENT; TECHNETIUM;

ADULT; AGED; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TUMOR LEVEL; FEMALE; GENE EXPRESSION; HEAD CANCER; HUMAN; MALE; NECK CANCER; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; BLOOD; CLINICAL TRIAL; HEAD AND NECK TUMOR; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; RADIOIMMUNOASSAY; SCINTISCANNING; TISSUE DISTRIBUTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; FEMALE; GLYCOPROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 0033624181     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics 1998. CA Cancer J. Clin., 48: 6-29, 1998.
2. Schuller, D. E., Metch, B., Stein, D. W., Mattox, D., and McCracken, J. D. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope, 98: 1205-1211, 1988.
3. Stell, P. M., and Rawson, N. S. B. Adjuvant chemotherapy in head and neck cancer. Br. J. Cancer, 61: 779-787, 1990.
4. Vokes, E. E., Weichselbaum, R. R., Lippman, S. M., and Hong, W. K. Head and neck cancer. N. Engl. J. Med., 328: 184-194, 1993.
5. Wessels, B. W., Harisiadis, L., and Carabell, S. C. Dosimetry and radiobiological efficacy of clinical radioimmunotherapy. J. Nucl. Med., 30: 827, 1989.
6. Schrijvers, A. H. G. J., Quak, J. J., Uyterlinde, A. M., Van Walsum, M., Meijer, C. J. L. M., Snow, G. B., and van Dongen, G. A. M. S. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res., 53: 4383-4390, 1993.
7. De Bree, R., Roos J. C., Quak, J. J., Den Hollander, W., Snow, G. B., and Van Dongen, G. A. M. S. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin. Cancer. Res., 1: 591-598, 1995.
8. Van Hal, N. L. W., Van Dongen, G. A. M. S., Rood-Knippels, E. M. C., Van der Valk, P., Snow, G. B., and Brakenhoff, R. H. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous cell carcinoma, recognizes a CD44 isoform. Int. J. Cancer, 68: 520-527, 1996.
9. Heider, K-H., Mulder, J-W. R., Ostermann, E., Susani, S., Patzelt, E., Pals, S. T., and Adolf, G. R. Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumor cells are expressed in normal tissues of humans and cynomolgus monkeys. Eur. J. Cancer, 31A: 2385-2391, 1995.
10. Jung, K., Lein, M., Weiss, S., Schnorr, D., Henke, W., and Loening, S. Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia. Eur. J. Cancer, 32A: 627-630, 1996.
11. Lesley, J., Hyman, R., and Kincade, P. W. CD44 and its interaction with extracellular matrix. Adv. Immunol., 54: 271-335, 1993.
12. Webb, D. S. A., Shimizu, Y., Van Seventer, G. A., Shaw, S., and Gerrard, T. L. LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science (Washington DC), 9: 1295-1297, 1990.
13. Thomas, L., Byers, H. R., Vink, J., and Stamenkovic, I. CD44H regulates tumor cell migration on hyaluronate-coated substrate. J. Cell Biol., 118: 971-977, 1992.
14. Günthert, U., Hofmann, M., Rudy, W., Reber, S., Zöller, M., Haussmann, I., Matzku, S., Wenzel, A., Ponta, H., and Herrlich, P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65: 13-24, 1991.
15. Seiter, S., Arch, R., Reber, S., Komitowski, D., Hofmann, M., Ponta, H., Herrlich, P., Matzku, S., and Zöller, M. Prevention of tumor metastasis formation by anti-variant CD44. J. Exp. Med., 177: 443-455, 1993.
16. Mulder, J-W. R., Kruyt, P. M., Sewnath, M., Oosting, J., Seldenrijk, C. A., Weidema, W. F., Offerhaus, G. J. A., and Pals, S. T. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet, 344: 1470-1472, 1994.
17. Stauder, R., Eisterer, W., Thaler, J., and Günthert, U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood, 85: 2885-2899, 1995.
18. Kaufmann, M., Heider, K-H., Sinn, H-P., Von Minckwitz, G., Ponta, H., and Herrlich, P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet, 345: 615-619, 1995.
19. Haggerty, J. G., Bretton, R. H., and Milstone, L. M. Identification and characterization of a cell surface proteoglycan on keratinocytes. J. Investig. Dermatol., 99: 374-380, 1992.
20. Salmi, M., Grön-Virta, K., Sointu, P., Grenman, R., Kalimo, H., and Jalkanen, S. Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. J. Cell Biol., 122: 431-442, 1993.
21. Kugelman, L. C., Ganguiy, S., Haggerty, J. G., Weissman, S. M., and Milstone, L. M. The core protein of epican, a heparan sulfate proteoglycan on keratinocytes, is an alternative form of CD44. J. Investig. Dermatol., 99: 886-891, 1992.
22. Schlom, J., Eggensperger, D., Colcher, D., Molinolo, A., Houchens, D., Miller, L. S., Hinkle, G., and Siler, K. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res., 52: 1067-1072, 1992.
23. Kievit, E., Pinedo, H. M., Schlüper, H. M. M., Haisma, H. J., and Boven, E. Comparison of the monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumor uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts. Br. J. Cancer. 73: 457-463, 1996.
24. Sobin, L. H., and Wittekind, C. (eds.). TNM Classification of Malignant Tumours, Ed. 5. New York: Wiley-Liss, Inc., 1997.
25. Van den Brekel, M. W. M., Stel, H. V., Castelijns, J. A., Nauta, J. J. P., Van der Waal, I., Valk, J., Golding, R. P., Meijer, C. J. L. M., and Snow, G. B. Cervical lymph node metastases: assessment of radiologic criteria. Radiology, 177: 379-384, 1990.
26. Van Gog, F. B., Visser, G. W. M., Klok, R., Van der Schors, R., Snow, G. B., and Van Dongen, G. A. M. S. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics. J. Nucl. Med., 37: 352-362, 1996.
27. Kittl, E. M., Ruckser, R., Rech-Weichselbraun, I., Hinterberger, W., and Bauer, K. Significant elevation of tumour-associated isoforms of soluble CD44 in serum of normal individuals caused by cigarette smoking. Eur. J. Clin. Chem. Clin. Biochem., 35: 81-84, 1997.
28. De Bree, R., Roos, J. C., Plaizier, M. A. B. D., Quak, J. J., Van Kamp, G. J., Den Hollander, W., Snow, G. B., and Van Dongen, G. A. M. S. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients. Br. J. Cancer, 75: 1049-1060, 1997.
29. Maraveyas A., Myers, M., Stafford, N., Rowlinson-Busza, G., Stewart, J. S. W., and Epenetos, A. A. Radiolabeled antibody combined with external radiotherapy for the treatment of head and neck cancer: reconstruction of a theoretical phantom of the larynx for radiation dose escalation to local tissues. Cancer Res., 55: 1020-1027, 1995.
30. Hansen, H. J., Newman, E. S., Ostella, F., Moskie, L. A., Sharkey, R. M., and Goldenberg, D. M. Preclinical comparison of two specific anti-carcinoembryonic antigen (CEA) MAbs, NP-4 and Immu-14, in athymic nude mice bearing GW-39 human colon carcinoma xenografts. Proc. Am. Assoc. Cancer Res., 30: 414, 1989.
31. van Osdol, W., Fujimori, K., and Weinstein, J. N. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier." Cancer Res., 57: 4776-4784, 1991.
32. Fujimori, K., Covell, D. G., Fletcher, J. E., and Weinstein, J. N. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J. Nucl. Med., 31: 1191-1198, 1990.
33. Juweid, M., Neumann, R., Paik, C., Perez-Bacete, M. J., Sato, J., van Osdol, W., and Weinstein, J. N. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res., 52: 5144-5153, 1992.
34. Hnatowich, D. J., Griffin, T. W., Kosciuczyk, C., Rusckowski, M., Childs, R. L., Mattis, M. J. A., Shealy, D., and Doherty, P. W. Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients. J. Nucl. Med., 26: 849-858, 1985.
35. Bosslet, K., Steinsträsser, A., Schwarz, A., Harthus, H. P., Lüben, G., Kuhlmann, L., and Sedlacek, H. H. Quantitative considerations supporting the irrelevance of circulating serum CEA for the immunoscintigraphic visualization of CEA expressing carcinomas. Eur. J. Nucl. Med., 14: 523-528, 1988.